TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note released on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $11.00 target price on the stock.

Several other analysts have also commented on TLSI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Lake Street Capital cut their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus target price of $8.67.

TriSalus Life Sciences Stock Up 0.6%

Shares of TriSalus Life Sciences stock opened at $4.76 on Wednesday. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The company’s 50 day moving average is $4.75 and its 200 day moving average is $4.33. The company has a market cap of $293.12 million, a price-to-earnings ratio of -3.66 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC bought a new stake in shares of TriSalus Life Sciences in the second quarter worth about $36,000. JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in TriSalus Life Sciences during the second quarter worth $47,000. Invesco Ltd. purchased a new position in TriSalus Life Sciences during the fourth quarter worth $72,000. Finally, Abel Hall LLC bought a new position in TriSalus Life Sciences during the fourth quarter valued at $73,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.